SVB Leerink Starts Trevi Therapeutics (TRVI) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Stifel Starts Trevi Therapeutics (TRVI) at Buy
June 3, 2019 7:16 AM EDTStifel analyst Annabel Samimy initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Trevi Therapeutics click here. For more ratings news on Trevi Therapeutics click here.
Shares of Trevi Therapeutics closed at $9.99 yesterday.
... MoreNeedham & Company Starts Trevi Therapeutics (TRVI) at Buy
June 3, 2019 7:12 AM EDTNeedham & Company analyst Serge Belanger initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Buy rating and a price target of $18.00.
The analyst comments "We are initiating coverage of Trevi Therapeutics (TRVI), a clinical-stage biopharma focused on the development of oral... More
BMO Capital Starts Trevi Therapeutics (TRVI) at Outperform
June 3, 2019 2:18 AM EDTBMO Capital analyst Gary Nachman initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Outperform rating and a price target of $15.00.
The analyst comments "Key product Nalbuphine ER has a solid track record and substantial evidence supporting its mechanism to treat various chronic... More
